Orphan Drugs Study Compares EMA's Significant Benefit With HTA's Relative Effectiveness Assessments
Executive Summary
A first of its kind study is underway to look at how the significant benefit assessment of orphan products by the European Medicines Agency compares with relative effectiveness assessments by health technology assessment bodies.
You may also be interested in...
New Head For EMA's Orphan Drugs Committee
A key priority for the new chair will involve reinforcing how the European Medicines Agency’s orphan drugs committee interacts and communicates with other scientific committees at the agency and other international partners.
EMA Works With HTAs To Support Earlier Relative Effectiveness Assessments
Information sharing initiative between European Medicines Agency and health technology assessment bodies has resulted in three joint relative effectiveness reports on new medicines.
EMA Boosts Transparency On Maintaining Orphan Status At Time Of Approval
New orphan maintenance assessment reports are expected to increase transparency around the European Medicines Agency's decision-making process on whether an orphan-designated drug continues to qualify as an orphan once it gets on to the market.